- Home
- NCNA vs BIAF Comparison
NCNA vs BIAF Comparison
Compare NCNA & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCNA
- BIAF
- Stock Information
- Founded
- NCNA 1997
- BIAF 2014
- Country
- NCNA United Kingdom
- BIAF United States
- Employees
- NCNA N/A
- BIAF N/A
- Industry
- NCNA Biotechnology: Pharmaceutical Preparations
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NCNA Health Care
- BIAF Health Care
- Exchange
- NCNA Nasdaq
- BIAF Nasdaq
- Market Cap
- NCNA 6.6M
- BIAF 7.6M
- IPO Year
- NCNA 2017
- BIAF 2022
- Fundamental
- Price
- NCNA $3.86
- BIAF $0.27
- Analyst Decision
- NCNA
- BIAF Hold
- Analyst Count
- NCNA 0
- BIAF 1
- Target Price
- NCNA N/A
- BIAF N/A
- AVG Volume (30 Days)
- NCNA 346.4K
- BIAF 1.7M
- Earning Date
- NCNA 08-20-2025
- BIAF 11-13-2025
- Dividend Yield
- NCNA N/A
- BIAF N/A
- EPS Growth
- NCNA N/A
- BIAF N/A
- EPS
- NCNA N/A
- BIAF N/A
- Revenue
- NCNA N/A
- BIAF $7,681,059.00
- Revenue This Year
- NCNA N/A
- BIAF N/A
- Revenue Next Year
- NCNA N/A
- BIAF $20.04
- P/E Ratio
- NCNA N/A
- BIAF N/A
- Revenue Growth
- NCNA N/A
- BIAF 4.99
- 52 Week Low
- NCNA $2.78
- BIAF $0.16
- 52 Week High
- NCNA $1,650.00
- BIAF $2.26
- Technical
- Relative Strength Index (RSI)
- NCNA 41.45
- BIAF 54.26
- Support Level
- NCNA $2.82
- BIAF $0.24
- Resistance Level
- NCNA $3.60
- BIAF $0.27
- Average True Range (ATR)
- NCNA 0.24
- BIAF 0.02
- MACD
- NCNA 0.43
- BIAF 0.00
- Stochastic Oscillator
- NCNA 74.48
- BIAF 79.75
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.